114 related articles for article (PubMed ID: 8320837)
1. [Angiotensin II receptor antagonist activities and mode of action of benzimidazole-7-carboxylic acid derivatives].
Naka T
Nihon Rinsho; 1993 Jun; 51(6):1575-9. PubMed ID: 8320837
[TBL] [Abstract][Full Text] [Related]
2. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Naka T; Kubo K; Inada Y; Nishikawa K
Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
5. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Naka T; Kubo K
Curr Pharm Des; 1999 Jun; 5(6):453-72. PubMed ID: 10390609
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological profiles of candesartan cilexetil (TCV-116)].
Inada Y
Nihon Rinsho; 1999 May; 57(5):1130-6. PubMed ID: 10361446
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Okamura M; Konishi Y; Nishimura M; Umetani N; Iwai J; Negoro N; Inoue T; Takeda T; Kanayama Y
Blood Press Suppl; 1994; 5():75-8. PubMed ID: 7889207
[TBL] [Abstract][Full Text] [Related]
9. Effects of an angiotensin II receptor antagonist, TCV-116, on insulin sensitivity in fructose-fed rats.
Shimamoto K; Matsuda K; Takizawa H; Higashiura K; Ura N; Iimura O
Blood Press Suppl; 1994; 5():113-6. PubMed ID: 7889192
[TBL] [Abstract][Full Text] [Related]
10. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Takeda K; Fujita H; Nakamura K; Uchida A; Tanaka M; Itoh H; Nakata T; Sasaki S; Nakagawa M
Blood Press Suppl; 1994; 5():94-8. PubMed ID: 7889211
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive activity of the novel, nonpeptide angiotensin II receptor antagonists BIBS 39 and BIBS 222 in conscious renal hypertensive rats.
Zhang J; Van Meel JC; Van Zwieten PA
Pharmacology; 1993 May; 46(5):241-7. PubMed ID: 8488169
[TBL] [Abstract][Full Text] [Related]
12. [Angiotensin II receptor antagonists: candesartan cilexetil].
Naka T; Kubo K; Nishikawa K; Inada Y; Furukawa Y
Yakugaku Zasshi; 2000 Dec; 120(12):1261-75. PubMed ID: 11193378
[TBL] [Abstract][Full Text] [Related]
13. Effects of the angiotensin II receptor antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects.
Ogihara T; Nagano M; Mikami H; Higaki J; Kohara K; Azuma J; Aoki T; Hamanaka Y
Clin Ther; 1994; 16(1):74-86. PubMed ID: 8205603
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil: a review of its preclinical pharmacology.
Nishikawa K; Naka T; Chatani F; Yoshimura Y
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Lambert DG; Champion HC; Kadowitz PJ
Can J Physiol Pharmacol; 1998 Feb; 76(2):133-40. PubMed ID: 9635151
[TBL] [Abstract][Full Text] [Related]
16. [Nonpeptide angiotensin II-receptor antagonists].
Inada Y; Wada T; Shibouta Y; Nishikawa K
Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):217-28. PubMed ID: 7959414
[TBL] [Abstract][Full Text] [Related]
17. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
[TBL] [Abstract][Full Text] [Related]
18. [Nonpeptide angiotensin II receptor antagonists].
Nishikawa K
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1873-80. PubMed ID: 8210431
[No Abstract] [Full Text] [Related]
19. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.
Noda M; Shibouta Y; Inada Y; Ojima M; Wada T; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
Biochem Pharmacol; 1993 Jul; 46(2):311-8. PubMed ID: 8347154
[TBL] [Abstract][Full Text] [Related]
20. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
Kito G; Morimoto S; Shiomi M
Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
